The price of Lorlatinib (lorlatinib) targeted drug entering into medical insurance

Lorlatinib (Lolatinib), as an important targeted drug, has been included in domestic medical insurance, which is good news for patients, because it means that their financial burden can be relieved to a certain extent. However, even if it is included in medical insurance, the price of lorlatinib is still relatively high, which has raised concerns about the reimbursement price of medical insurance.

It is understood that the price of lorlatinib (lorlatinib) in the domestic market is about 10,000 to 20,000 yuan, which may be a large sum for many patients. Medical insurance reimbursement prices may vary because medical insurance policies and reimbursement standards may differ in different regions. Patients can obtain specific medical insurance reimbursement price information by consulting the local hospital pharmacy.

In comparison, the price of lorlatinib (lorlatinib) in foreign markets is also different. The price of original drugs in Türkiye is relatively cheap, about more than 7,000 yuan, while the price of original drugs in Hong Kong is as high as about 30,000 yuan. In addition, generic drugs produced in some countries are also available on the market, with prices generally ranging from more than one thousand yuan to several thousand yuan. Although the ingredients of original drugs and generic drugs are basically the same, patients need to make sure to choose regular channels when purchasing to ensure the quality and safety of the drugs.

Lorlatinib (lorlatinib) included in medical insurance Although the price is still high, it undoubtedly provides some financial support for some patients. The role of medical insurance is to reduce the cost of treatment for patients and make it easier for them to obtain necessary treatment. However, there are still some challenges that need to be faced, such as differences in medical insurance reimbursement standards and limitations in medical insurance coverage, which may affect the rights and interests of some patients. Therefore, the improvement and optimization of medical insurance policies and the reasonable adjustment of medical insurance reimbursement prices are issues that require current focus.

In general, Lorlatinib as an important lung cancer targeted drug, its inclusion in medical insurance is undoubtedly good news for patients, but relevant policies still need to be further improved to ensure that patients can obtain fair and reasonable medical protection.